Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -8.85% is 26% above its 1-year average of -11.96%, near the high end of its 1-year range (-13.47%–-8.85%).
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-8.85%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Basel Medical Group Ltd Ordinary Shares
Market Cap
$4.96M
EBITDA Margin
-8.85%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.99M
EBITDA Margin
-2579.35%
TTM Avg
-2579.35%
3Y Avg
-2089.74%
5Y Avg
-2089.74%
Market Cap
$4.79M
EBITDA Margin
-1127.44%
TTM Avg
-14514.89%
3Y Avg
-11694.21%
5Y Avg
-11694.21%
Market Cap
$4.42M
EBITDA Margin
-445.85%
TTM Avg
-1797.00%
3Y Avg
-2252.67%
5Y Avg
-1514.30%
Market Cap
$4.41M
EBITDA Margin
-2411.68%
TTM Avg
-15920.55%
3Y Avg
-15920.55%
5Y Avg
-10610.40%
Market Cap
$4.32M
EBITDA Margin
-159.06%
TTM Avg
-237.19%
3Y Avg
-222.87%
5Y Avg
-159.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Basel Medical Group Ltd Ordinary Shares (BMGL) | $4.96M | -8.85% | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
| CalciMedica, Inc. (CALC)vs › | $4.85M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | -1127.44% | -14514.89% | -11694.21% | -11694.21% |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | -445.85% | -1797.00% | -2252.67% | -1514.30% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | -2411.68% | -15920.55% | -15920.55% | -10610.40% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | -159.06% | -237.19% | -222.87% | -159.05% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A | N/A | N/A | N/A |
Gross Margin
77.7%
EBITDA Margin
-8.8%
Operating Margin
-19.3%
Net Margin
-106.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -10.45% |
| 2025-06-30 | -13.47% |
